Sector News

Amgen Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary

May 20, 2015
Life sciences
/PRNewswire/ – Amgen today announced the appointment of Jonathan P. Graham as senior vice president, general counsel and secretary, effective July 13, 2015. He will be responsible for Amgen’s legal operations, reporting to Robert A. Bradway, chairman and chief executive officer. Graham will succeed David J. Scott who is retiring Aug. 31, 2015.
 
Graham, 55, joins Amgen from Danaher Corporation, where he has served as senior vice president and general counsel, responsible for all legal, governance, regulatory, risk, and compliance matters.
 
Previously, Graham was vice president, litigation and legal policy at General Electric Company and a partner at Williams & Connolly LLP. He also served as a law clerk to the Honorable Joseph T. Sneed, U.S. Court of Appeals for the Ninth Circuit. Graham received his bachelor’s degree from Pitzer College and his J.D. from the University of Texas School of Law, where he was editor-in-chief of the Texas Law Review. 
 
Bradway said, “We are excited to have Jon join our team.  His proven leadership skills and depth of experience will serve us well as we drive our agenda for growth.”
 
Source: Amgen

Related News

September 25, 2020

Novo Nordisk tees up phase 3 trial for once-weekly insulin

Life sciences

People with Type 2 diabetes are no strangers to needles, with some injecting bolus insulin after meals, others injecting basal insulin once or twice a day, and others still doing […]

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]